anonymous
Guest
anonymous
Guest
Help me understand how this company can possibly go IPO:
Why would anyone want to invest in Galderma?
- Epiduo, Differin, Oracea, Loceryl, Metvix, Mirvaso, Soolantra, Restylane, Cetaphil are old products with no innovation in the pipeline.
- Azzalure/Dysport is not ours
- QM1114 faces a lawsuit
- Nemolizumab is late to market
In July 2023, Ipsen notified Galderma of the termination R&D collaboration related to the neurotoxin programs. No new products? Link: Ipsen delivers solid H1 2023 results and upgrades its full-year guidance